In an unprecedented move set to revolutionize emergency cardiac care, Asamedic and Bormioli Pharma have formed a groundbreaking partnership to commercialize Coxor, a 300mg Acetylsalicylic acid medication designed for the urgent treatment of suspected acute myocardial infarction. Unlike traditional aspirin tablets that require water for ingestion, Coxor is delivered in liquid form through Bormioli Pharma’s innovative EasyRec system, a specialized dual-chamber packaging kit. This system keeps the powdered medication stable and well-protected until it is needed, which allows for rapid reconstitution and facilitates quick self-administration without the necessity of water. By offering faster absorption into the bloodstream, Coxor dramatically improves the chances of survival during heart attack emergencies.
Geir Ivar Westen, CEO of Asamedic, emphasized how critical this partnership is in transforming emergency cardiac treatment. He noted that the EasyRec system’s ability to expedite drug delivery directly addresses the time-sensitive nature of treating myocardial infarctions, which can mean the difference between life and death. The result is a product that not only improves patient outcomes but also sets a new standard for the pharmaceutical industry’s approach to emergency medications. On the other hand, Andrea Lodetti, CEO of Bormioli Pharma, highlighted that this collaboration beautifully illustrates how pharmaceutical companies can work effectively with packaging manufacturers to make medications more accessible and effective. Their shared vision leverages each company’s strengths, resulting in a product that is both medically advanced and practical for real-world emergency use.
Fast-Track to Global Deployment
Asamedic and Bormioli Pharma have partnered to launch Coxor, a revolutionary 300mg Acetylsalicylic acid medication for emergency treatment of suspected acute myocardial infarction. Unlike regular aspirin, Coxor comes in a liquid form, thanks to Bormioli Pharma’s innovative EasyRec system, a dual-chamber packaging that keeps the powdered medication stable until it’s needed. This allows for quick reconstitution and immediate self-administration without water, leading to faster absorption and improved survival rates during heart attacks.
Geir Ivar Westen, CEO of Asamedic, stressed the critical impact of this partnership on emergency cardiac care. He pointed out that the EasyRec system’s ability to hasten drug delivery is crucial in the time-sensitive treatment of myocardial infarctions, often making the difference between life and death. This collaboration not only enhances patient outcomes but also revolutionizes emergency medication standards. Andrea Lodetti, CEO of Bormioli Pharma, noted that this partnership highlights how pharmaceutical and packaging companies can work together to make medications more effective and accessible. By combining their strengths, they have created a product that is both advanced and practical for real-world emergencies.
